6 assets in Bone Cancer

Therapeutic assets addressing Bone Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Bone Cancer	Actuate Therapeutics Inc.	P2	B (60)
Irinotecan Bone Cancer	Actuate Therapeutics Inc.	P2	B (60)
Carboplatin Bone Cancer	Actuate Therapeutics Inc.	P2	CCC (53)
Lomustine Bone Cancer	Actuate Therapeutics Inc.	P2	CCC (53)
Elraglusib Bone Cancer	Actuate Therapeutics Inc.	P2	CCC (50)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAMETHYLENEPHOSPHONIC ACID Bone Cancer	QSAM Therapeutics, Inc.	P1	CC (43)